## Structure based design of degraders

Radoslaw Nowak<sup>1</sup>

<sup>1</sup>Dana-Farber Cancer Institute
nowak@crystal.harvard.edu

Small molecule degraders have shown considerable promise as a new pharmacological modality. With the mounting structural information on degrader mediated ligase-substrate interactions we are beginning to understand the rationale for target recruitment and selectivity. This presentation will describe a structural basis for accelerating degrader design.